Fundz
Free weekly newsletter

Get the free weekly funding digest

The new funding rounds, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New funding rounds, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Industry Trends

See who's moving and how much in your market

No credit card required Weekly funding digest

CellCentric completes $220 million Series D financing led by Venrock Healthcare to advance inobrodib trials for multiple myeloma.

PRIVATEMay 06, 2026•about 1 month ago

Amount Raised

$220 Million

Round Type

series d

CambridgeBiotechnologyHealth Care

Investors

American Cancer Society Bright EdgeAvego Bio Science CapitalPfizerForbionRa Capital ManagementHbm HealthcareSofinnova PartnersFidelity Management & Research CompanyVenrock Healthcare Capital Partners

Description

CellCentric has announced an oversubscribed $220 million Series D financing to support pivotal trials of inobrodib. The financing was led by Venrock Healthcare Capital Partners and included participation from various investors. Proceeds will fund the Phase 2 DOMMINO-1 and Phase 3 DOMMINO-2 trials. The CEO emphasizes the significant unmet need in treatments for multiple myeloma.

Company Information

Company

CellCentric

Location

Cambridge, England, United Kingdom

About

CellCentric is a clinical-stage biotechnology company advancing Inobrodib, a new treatment for cancer, particularly multiple myeloma. This small molecule drug targets p300/CBP, reducing the expression of key cancer drivers, MYC and IRF4. It is delivered as an oral capsule, allowing patients to use it at home without the need for intensive monitoring. The drug has a favorable safety profile, making it suitable for those unable to access or tolerate other treatment options.

Related People

Suggested for you
1 contact

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for CellCentric's next move

Learn about Strategic plan

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.

Watching CellCentric? See every signal — funding, hires, M&A, contracts, sentiment.

Request a demoChoose your plan